Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression

BACKGROUND & AIMS: Bulevirtide (BLV) is a novel antiviral drug licensed for the treatment of chronic hepatitis D. Data on the safety and efficacy of stopping BLV therapy upon long-term HDV-RNA suppression are scarce. METHODS: A total of seven patients (age, 31–68 years, four with cirrhosis) incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Jachs, Mathias, Panzer, Marlene, Hartl, Lukas, Schwarz, Michael, Balcar, Lorenz, Camp, Jeremy V., Munda, Petra, Mandorfer, Mattias, Trauner, Michael, Aberle, Stephan W., Zoller, Heinz, Reiberger, Thomas, Ferenci, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285645/
https://www.ncbi.nlm.nih.gov/pubmed/37360907
http://dx.doi.org/10.1016/j.jhepr.2023.100751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285645/
https://www.ncbi.nlm.nih.gov/pubmed/37360907
http://dx.doi.org/10.1016/j.jhepr.2023.100751

Ejemplares similares